Simulations Plus

Simulations Plus develops modeling and simulation software and provides consulting services to the pharmaceutical and biotechnology industries. Its work sits at the intersection of artificial intelligence and machine learning with established pharmacological methods: physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology (QSP), pharmacometric and PK/PD modeling, ADMET property prediction, liver toxicity assessment, crystallization simulation and formulation development modeling. The company has operated for over 30 years and is publicly traded on NASDAQ under the ticker SLP.

Its product portfolio includes GastroPlus, for PBPK modeling; ADMET Predictor, for predicting absorption, distribution, metabolism, excretion and toxicity properties; MonolixSuite, for PK/PD modeling; DILIsym, for drug-induced liver injury assessment; and Thales, for crystallization simulation. Beyond software, expert consultants work directly with clients on research challenges, applying data-driven analysis to inform go/no-go decisions across drug discovery, drug development, clinical operations and commercialization. Clients include pharmaceutical and biotechnology firms as well as regulatory agencies worldwide.

The company is headquartered in Lancaster, California, with an additional office in Research Triangle Park, North Carolina. A Learning Services division runs workshops, online courses and certification programs, alongside its work of accelerating drug development while reducing costs and improving decision-making.